Patrick Y Wen

2.2k total citations · 1 hit paper
16 papers, 1.6k citations indexed

About

Patrick Y Wen is a scholar working on Genetics, Neurology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Patrick Y Wen has authored 16 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 7 papers in Neurology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Patrick Y Wen's work include Glioma Diagnosis and Treatment (16 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Brain Metastases and Treatment (4 papers). Patrick Y Wen is often cited by papers focused on Glioma Diagnosis and Treatment (16 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Brain Metastases and Treatment (4 papers). Patrick Y Wen collaborates with scholars based in United States, Netherlands and Canada. Patrick Y Wen's co-authors include Jeffrey J. Olson, Hui‐Kuo G. Shu, Erwin G. Van Meir, Costas G. Hadjipanayis, David A. Reardon, Ingo K. Mellinghoff, E. Q. Lee, Andrew D. Norden, D. Schiff and Lakshmi Nayak and has published in prestigious journals such as CA A Cancer Journal for Clinicians, Neuro-Oncology and Journal of Neuro-Oncology.

In The Last Decade

Patrick Y Wen

13 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma

2010 1.1k citations Erwin G. Van Meir, Costas G. Hadjipanayis et al. CA A Cancer Journal for Clinicians profile →

Peers

Patrick Y Wen

GENET

ONCOL

PRM

Fumiharu Ohka Japan

Olivier Keunen Luxembourg

Marta Mellai Italy

Sarah Lapointe Canada

Ana C. deCarvalho United States

Deric M. Park United States

Kelly Burrell Canada

Jigisha P. Thakkar United States

Barbara Klink Germany

Fumiharu Ohka Japan

Patrick Y Wen

1.0k ×1.3

525 ×0.7

GENET

678 ×1.4

309 ×1.2

ONCOL

167 ×0.8

PRM

Citations per year, relative to Patrick Y Wen Patrick Y Wen (= 1×) peers Fumiharu Ohka

Countries citing papers authored by Patrick Y Wen

Since Specialization

Citations

This map shows the geographic impact of Patrick Y Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Y Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Y Wen more than expected).

Fields of papers citing papers by Patrick Y Wen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Y Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Y Wen. The network helps show where Patrick Y Wen may publish in the future.

Co-authorship network of co-authors of Patrick Y Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Y Wen. A scholar is included among the top collaborators of Patrick Y Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Y Wen. Patrick Y Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Perreault, Sébastien, Marjolein Geurts, Jasia Mahdi, et al.. (2025). Point/counterpoint: Upfront BRAF inhibition for adult BRAF-mutant high-grade gliomas. Neuro-Oncology. 27(11). 2804–2811.

Schiff, David, Xiaobu Ye, Jing Li, et al.. (2025). Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas. Neuro-Oncology. 28(2). 485–494.

Wen, Patrick Y, et al.. (2024). Clinical trial design for novel targeted agents in neuro-oncology. Journal of Neuro-Oncology. 171(1). 21–33. 1 indexed citations

Dmello, Crismita, Andrew Brenner, David Piccioni, et al.. (2024). Phase II trial of blood–brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma. Neuro-Oncology Advances. 6(1). vdae186–vdae186. 6 indexed citations

Wen, Patrick Y, et al.. (2024). The Role of Mutant IDH Inhibitors in the Treatment of Glioma. Current Neurology and Neuroscience Reports. 24(12). 631–643. 3 indexed citations

Chukwueke, Ugonma, Timothy S. Sannes, Daniel Chiu, et al.. (2024). Glioma resource outreach with support: A program to identify and initiate supportive care interventions for unmet needs among adult lower-grade glioma patients. Neuro-Oncology Practice. 12(1). 87–99.

Avila, Edward K., Steven Tobochnik, Sara K. Inati, et al.. (2023). Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management. Neuro-Oncology. 26(1). 7–24. 33 indexed citations

Galanis, Evanthia, S. Keith Anderson, Erin Twohy, et al.. (2022). Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances. 4(1). vdac041–vdac041. 6 indexed citations

Lee, E. Q., David A. Reardon, D. Schiff, et al.. (2015). Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro-Oncology. 17(6). 862–867. 103 indexed citations

10.

Reardon, David A., Patrick Y Wen, & Ingo K. Mellinghoff. (2014). Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. Neuro-Oncology. 16(suppl 8). viii7–viii13. 81 indexed citations

11.

Schiff, D., E. Q. Lee, Lakshmi Nayak, et al.. (2014). Medical management of brain tumors and the sequelae of treatment. Neuro-Oncology. 17(4). 488–504. 99 indexed citations

12.

Rahman, Rifaquat, Andrew D. Norden, David A. Reardon, et al.. (2014). Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro-Oncology. 16(11). 1523–1529. 19 indexed citations

13.

Armstrong, Terri S., Patrick Y Wen, Mark R. Gilbert, & David Schiff. (2012). Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro-Oncology. 14(10). 1203–1214. 53 indexed citations

14.

Scott, Brian J., et al.. (2010). Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-Oncology. 12(6). 603–607. 51 indexed citations

15.

Prados, Michael, Timothy F. Cloughesy, Meghna Samant, et al.. (2010). Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13(1). 143–151. 61 indexed citations

16.

Meir, Erwin G. Van, et al.. (2010). Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. CA A Cancer Journal for Clinicians. 60(3). 166–193. 1091 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact